Basel, Switzerland, 30 August 2010 - Lonza enters the viral based-manufacturing market today with its purchase of Vivante GMP Solutions, Inc. The acquisition advances Lonza’s strategy to broaden its biologics custom service offering for the growing viral vaccine and gene therapy markets.
Based in Houston, Texas, Vivante is a custom manufacturing organization dedicated to producing GMP viral-based therapeutics. The company’s viral-vaccine production services will be enhanced by Lonza’s established expertise in expression technologies and large-scale manufacturing platforms. Additionally, Vivante’s experience with pre-clinical through late- stage supply of viral vector-based products will compliment Lonza’s growing cellular and gene therapy process development and manufacturing capabilities.
“Lonza is strategically committed to being successful in the growing viral marketplace. Vivante’s expertise will allow us to accelerate our entry into the viral-based manufacturing arena”, said David Smith, Lonza’s Head of Therapeutic Cell Solutions.
J. David Enloe Jr., Vivante’s founder, president and CEO, added, “We could not be happier with the opportunity to be at the forefront of Lonza’s expansion into the viral vaccine and vector market. We believe that the combination of Vivante’s expertise with the technical know-how, financial resources, and global reach that Lonza offers will be a tremendous advantage for our clients, both present and future.”
Effective today, Enloe and Vivante’s employees have joined Lonza and will operate as Lonza’s Viral-based Therapeutics Business.
About Vivante GMP Solutions, Inc.
Vivante provides its clients with flexible, disposable, scalable viral-based GMP production knowledge and capabilities to convert early-stage production into robust and scalable therapeutic products for clinical and commercial use. Vivante offers its clients access to proprietary quality and validation systems, and broad GMP knowledge systems. Vivante operates a state-of-the-art GMP clean room facility including production and fill/finish capabilities, along with high quality research and development and Quality Control operations. In addition to its GMP manufacturing service, Vivante offers process development and optimization, Quality Control analytical testing, and on- and off-site GMP product storage and distribution to clinical trial sites.
For more information please visit www.lonza.com/viral Lonza Group Ltd Muenchensteinerstrasse 38 CH-4002 Basel, Switzerland www.lonza.com
About Lonza Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts, which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets.
Lonza is headquartered in Basel, Switzerland and is listed on the SIX Swiss Exchange. In 2009, Lonza had sales of CHF 2.690 billion. Further information can be found at www.lonza.com.
